Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001213900-24-100303
Filing Date
2024-11-20
Accepted
2024-11-19 19:35:37
Documents
73
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-Q ea0221925-10qa1_cero.htm   iXBRL 10-Q/A 1051153
2 CERTIFICATION ea022192501ex31-1_cero.htm EX-31.1 10791
3 CERTIFICATION ea022192501ex31-2_cero.htm EX-31.2 9987
4 CERTIFICATION ea022192501ex32-1_cero.htm EX-32.1 4496
5 CERTIFICATION ea022192501ex32-2_cero.htm EX-32.2 4842
  Complete submission text file 0001213900-24-100303.txt   6195954

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cero-20240930.xsd EX-101.SCH 61788
7 XBRL CALCULATION FILE cero-20240930_cal.xml EX-101.CAL 37328
8 XBRL DEFINITION FILE cero-20240930_def.xml EX-101.DEF 312587
9 XBRL LABEL FILE cero-20240930_lab.xml EX-101.LAB 537683
10 XBRL PRESENTATION FILE cero-20240930_pre.xml EX-101.PRE 312247
77 EXTRACTED XBRL INSTANCE DOCUMENT ea0221925-10qa1_cero_htm.xml XML 759647
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

IRS No.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-40877 | Film No.: 241477867
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)